KDR and adenocarcinoma: In a large pan-cancer cohort of 7525 samples, Li AM et al. [9] demonstrated up-regulated VEGF-A transcript levels in tumors with TP53 mutations, particularly in adenocarcinomas, regardless of their organ of origin, while VEGFR2 expression levels were not significantly modified by TP53 mutational status or reduced in squamous carcinomas.